Evorpacept in combination with PADCEV®, an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology or the Company) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block...
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology or the Company) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block...
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology or the Company) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block...
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology or the Company) (Nasdaq: ALXO), an immuno-oncology company developing therapies that...
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology or the Company) (Nasdaq: ALXO), an immuno-oncology company developing therapies that...
Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (œR2) Evorpacept plus R2 was well tolerated with a safety profile...
ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
ALX Oncology Announces Evorpacept Clinical Abstracts Accepted for Presentation